YMAB News and Press, Y-mAbs Therapeutics Inc. From 01/27/23

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 27, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Y-mAbs To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - January 26, 2023) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...

New York, New York--(Newsfile Corp. - January 26, 2023) - Wolf Popper LLP reminds investors in Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) common stock during the Class Period October 6, 2020 through October 28, 2022 that they have until Monday, March 20, 2023, to seek appointment as lead plaintiff ...

New York, New York--(Newsfile Corp. - January 24, 2023) - Levi & Korsinsky, LLP notifies investors in Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ: YMAB) of a class action securities lawsuit. The lawsuit on behalf of Y-mAbs investors has been commenced in the the United St...

NEW YORK, NY / ACCESSWIRE / January 20, 2023 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Y-mAbs Therapeutics, Inc. ("Y-mAbs" or the "Company") (NASDAQ:YMAB) and reminds investors of the March 20, 2023 deadline to seek the role of ...

Boston, Massachusetts--(Newsfile Corp. - January 20, 2023) - Block & Leviton announces that a class action lawsuit has been filed against Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for securities law violations. Investors who purchased shares and have lost money are encouraged to contact the f...

Y-mAbs Therapeutics ( NASDAQ: YMAB ) will let go of 35% of its workforce and prioritize its efforts of the commercialization of Danyelza (naxitamab) for neuroblastoma as part of a strategic restructuring . Annual operating expenses are expected to decline by 28% -- $115M-$120M -- ...

Estimated 28% reduction in annual operating expenses for 2023 compared to previously announced guidance for 2022 of $162-167 million; Estimated total cash burn for 2023, including restructuring expenses, expected to be $50-55 million, expected to extend cash runway into Q1 2026 based on r...

NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatmen...

Y-mAbs Therapeutics ( NASDAQ: YMAB ) said it signed a distribution agreement with WEP Clinical for an early access program for its neuroblastoma drug Danyelza (naxitamab-gqgk) 40mg/10mL Injection in Europe. Neuroblastoma is a cancer which develops from immature nerve cells found i...